These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 16737674)

  • 1. NCCN Task Force Report: Bone Health and Cancer Care.
    Theriault RL; Biermann JS; Brown E; Brufsky A; Demers L; Grewal RK; Guise T; Jackson R; McEnery K; Podoloff D; Ravdin P; Shapiro CL; Smith M; Van Poznak CH
    J Natl Compr Canc Netw; 2006 May; 4 Suppl 2():S1-20; quiz S21-2. PubMed ID: 16737674
    [TBL] [Abstract][Full Text] [Related]  

  • 2. NCCN Task Force Report: Bone Health in Cancer Care.
    Gralow JR; Biermann JS; Farooki A; Fornier MN; Gagel RF; Kumar RN; Shapiro CL; Shields A; Smith MR; Srinivas S; Van Poznak CH
    J Natl Compr Canc Netw; 2009 Jun; 7 Suppl 3(Suppl 3):S1-32; quiz S33-5. PubMed ID: 19555589
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Understanding treatments for bone loss and bone metastases in patients with prostate cancer: a practical review and guide for the clinician.
    Higano CS
    Urol Clin North Am; 2004 May; 31(2):331-52. PubMed ID: 15123412
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bone health in adult cancer survivorship.
    Lustberg MB; Reinbolt RE; Shapiro CL
    J Clin Oncol; 2012 Oct; 30(30):3665-74. PubMed ID: 23008309
    [TBL] [Abstract][Full Text] [Related]  

  • 5. NCCN Task Force Report: Bone Health In Cancer Care.
    Gralow JR; Biermann JS; Farooki A; Fornier MN; Gagel RF; Kumar R; Litsas G; McKay R; Podoloff DA; Srinivas S; Van Poznak CH
    J Natl Compr Canc Netw; 2013 Aug; 11 Suppl 3():S1-50; quiz S51. PubMed ID: 23997241
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Age, body mass index, and serum prostate-specific antigen correlate with bone loss in men with prostate cancer not receiving androgen deprivation therapy.
    Conde FA; Sarna L; Oka RK; Vredevoe DL; Rettig MB; Aronson WJ
    Urology; 2004 Aug; 64(2):335-40. PubMed ID: 15302490
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Secondary osteoporosis UPDATE. Pathophysiology and management of cancer treatment-induced bone loss/fractures].
    Yoneda T
    Clin Calcium; 2010 May; 20(5):690-9. PubMed ID: 20445280
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Background to and management of treatment-related bone loss in prostate cancer.
    Berruti A; Tucci M; Terrone C; Gorzegno G; Scarpa RM; Angeli A; Dogliotti L
    Drugs Aging; 2002; 19(12):899-910. PubMed ID: 12495366
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cancer treatment-induced bone loss (CTIBL): pathogenesis and clinical implications.
    D'Oronzo S; Stucci S; Tucci M; Silvestris F
    Cancer Treat Rev; 2015 Nov; 41(9):798-808. PubMed ID: 26410578
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bone: best papers of the year 2017.
    Laurent MR
    Arch Osteoporos; 2018 Mar; 13(1):29. PubMed ID: 29546647
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Screening and management of osteoporosis in breast cancer patients on aromatase inhibitors.
    Gibson K; O'Bryant CL
    J Oncol Pharm Pract; 2008 Sep; 14(3):139-45. PubMed ID: 18719068
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Prostate cancer and Cancer Treatment-Induced Bone Loss(CTIBL)].
    Matsushima H
    Clin Calcium; 2016 Jul; 26(7):1039-45. PubMed ID: 27346316
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Osteoporosis in breast and prostate cancer survivors.
    Hoff AO; Gagel RF
    Oncology (Williston Park); 2005 Apr; 19(5):651-8. PubMed ID: 15945345
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [InoPro trial: collaboration between urologists and primary care physicians in the treatment of osteoporosis in prostate cancer patients].
    Laufer M; Keller T; Gershman V; Ferman Z; Sarid M; Leibovitch I
    Harefuah; 2014; 153(3-4):151-4, 240. PubMed ID: 24791553
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bone health in breast cancer survivors.
    Abdel-Razeq H; Awidi A
    J Cancer Res Ther; 2011; 7(3):256-63. PubMed ID: 22044804
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Bone and Men's Health. Bisphosphonate therapy for prostate cancer].
    Suzuki H; Kamiya N; Yano M; Endo T; Takano M; Kawamura K; Imamoto T; Ichikawa T
    Clin Calcium; 2010 Feb; 20(2):258-66. PubMed ID: 20118519
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prevalence of secondary causes of bone loss among breast cancer patients with osteopenia and osteoporosis.
    Camacho PM; Dayal AS; Diaz JL; Nabhan FA; Agarwal M; Norton JG; Robinson PA; Albain KS
    J Clin Oncol; 2008 Nov; 26(33):5380-5. PubMed ID: 18955450
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Osteoporosis in patients with breast and prostate cancer: effect of disease and treatment modalities.
    Legakis I; Syrigos K
    Endocr Metab Immune Disord Drug Targets; 2013 Jun; 13(2):168-74. PubMed ID: 23244490
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Managing bone health with zoledronic acid: a review of randomized clinical study results.
    Hadji P
    Climacteric; 2011 Jun; 14(3):321-32. PubMed ID: 21182431
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Osteopenia-osteoporosis syndrome in patients with thalassemia: understanding of type of bone disease and response to treatment.
    Chatterjee R; Bajoria R
    Hemoglobin; 2009; 33 Suppl 1():S136-8. PubMed ID: 20001617
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.